Goldman Sachs Maintains St. Jude Medical Neutral Rating (STJ)

Goldman Sachs maintained its St. Jude Medical STJ Neutral rating in a research report published today. In the report, Goldman Sachs states, "St. Jude Medical's annual investor meeting highlighted 18 growth drivers, which should collectively comprise about $8 bn in new market opportunity by 2014, in our view. This compares to the current markets in which St. Jude competes that comprise about $20 bn in total revenues. Including the new growth drivers, the end-user markets where St. Jude competes will increase about 60% by 2014." Shares of St. Jude Medical were at $41.98 in after hours trading at the time of posting, up 0.05% from Friday's market close.